{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+4+Liver+Cancer", "query": { "condition": "Stage 4 Liver Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 220, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+4+Liver+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T04:07:56.409Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04605731", "title": "Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BCLC Stage B Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-08-03", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04605731" }, { "nct_id": "NCT00324727", "title": "Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intraocular Melanoma", "Melanoma (Skin)", "Metastatic Cancer" ], "interventions": [ { "name": "melphalan", "type": "DRUG" }, { "name": "regional chemotherapy", "type": "DRUG" }, { "name": "systemic chemotherapy", "type": "DRUG" }, { "name": "hepatic artery embolization", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 93, "start_date": "2006-02", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2021-06-21", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 12, "location_summary": "Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324727" }, { "nct_id": "NCT00019760", "title": "Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Colon Cancer", "Liver Metastases", "Stage IV Rectal Cancer", "Recurrent Rectal Cancer", "Stage IV Colon Cancer" ], "interventions": [ { "name": "floxuridine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1999-04", "completion_date": "2002-03", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019760" }, { "nct_id": "NCT00103142", "title": "Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "falimarev", "type": "BIOLOGICAL" }, { "name": "inalimarev", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Michael Morse, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2005-02", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2015-10-14", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Durham, North Carolina + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103142" }, { "nct_id": "NCT03896646", "title": "Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Hepatobiliary Iminodiacetic Acid Scan", "type": "OTHER" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Yttrium Y 90 Glass Microspheres", "type": "RADIATION" }, { "name": "Yttrium-90 Microsphere Radioembolization", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2019-10-10", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896646" }, { "nct_id": "NCT06342440", "title": "Early Detection of Advanced Adenomas and Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Polyp", "Colorectal Adenocarcinoma", "Colorectal Disorders", "Colorectal Dysplasia", "Colorectal Cancer Stage I", "Colorectal Cancer Stage II", "Colorectal Cancer Stage III", "Colorectal Cancer Stage IV", "Colorectal Neoplasms Malignant", "Colorectal Serrated Adenocarcinoma", "Colorectal Adenoma With Severe Dysplasia", "Colorectal Adenoma With Mild Dysplasia", "Colorectal Adenoma With Moderate Dysplasia", "Colorectal Adenoma and Carcinoma 1", "Colorectal Adenomatous Polyp", "Colorectal Adenocarcinoma Metastatic in the Liver" ], "interventions": [ { "name": "DENEB", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2020-03-15", "completion_date": "2028-06-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 2, "location_summary": "Monrovia, California • San Diego, California", "locations": [ { "city": "Monrovia", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06342440" }, { "nct_id": "NCT06342427", "title": "Stomach Cancer Exosome-based Detection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Gastric Cancer Stage", "Gastric Neoplasm", "Gastric Lesion", "Gastric Cancer in Situ", "Gastric Cancer Stage IV", "Gastric Cancer Stage IIIB", "Gastric Cancer Stage III", "Gastric Cancer Stage IB", "Gastric Cancer Stage IA", "Gastric Cancer, Stage 0", "Gastric Cancer Stage IIIA", "Gastric Cancer Stage II", "Gastric Cancer TNM Staging", "Gastric Cancer Metastatic to Lung", "Gastric Cancer Metastatic to Liver", "Gastric Cancer Stage I", "Gastric Cancer TNM Staging Primary Tumor (T) T2B" ], "interventions": [ { "name": "DESTINEX", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 809, "start_date": "2023-03-15", "completion_date": "2024-06-15", "has_results": false, "last_update_posted_date": "2024-07-08", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06342427" }, { "nct_id": "NCT01425879", "title": "MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Adult Hepatocellular Carcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Recurrent Adult Liver Carcinoma", "Recurrent Gallbladder Carcinoma", "Stage IV Distal Bile Duct Cancer", "Stage IV Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Carcinoma", "Unresectable Gallbladder Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2011-04", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-06-17", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 8, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425879" }, { "nct_id": "NCT04941287", "title": "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Distal Bile Duct Adenocarcinoma", "Metastatic Gallbladder Carcinoma", "Metastatic Intrahepatic Cholangiocarcinoma", "Recurrent Distal Bile Duct Adenocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Liver Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Varlilumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2021-12-15", "completion_date": "2026-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04941287" }, { "nct_id": "NCT03695250", "title": "BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "IDO1 Inhibitor BMS-986205", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Edward Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-10-16", "completion_date": "2021-03-12", "has_results": true, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-07-23T04:07:56.409Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03695250" } ] }